Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
44.88
+1.56 (3.60%)
At close: Aug 22, 2025, 4:00 PM
45.65
+0.77 (1.72%)
After-hours: Aug 22, 2025, 4:42 PM EDT
Supernus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts that cover Supernus Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $41, which forecasts a -8.65% decrease in the stock price over the next year. The lowest target is $36 and the highest is $46.
Price Target: $41 (-8.65%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Supernus Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $42 → $46 | Buy | Maintains | $42 → $46 | +2.50% | Aug 6, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Reiterates $36 | Hold | Reiterates | $36 | -19.79% | Feb 26, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy → Hold Downgrades $57 → $36 | Buy → Hold | Downgrades | $57 → $36 | -19.79% | Feb 19, 2025 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $41 → $36 | Buy → Hold | Downgrades | $41 → $36 | -19.79% | Sep 11, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $45 → $41 | Buy | Maintains | $45 → $41 | -8.65% | Feb 28, 2024 |
Financial Forecast
Revenue This Year
653.90M
from 661.82M
Decreased by -1.20%
Revenue Next Year
756.85M
from 653.90M
Increased by 15.74%
EPS This Year
1.73
from 1.32
Increased by 31.11%
EPS Next Year
2.41
from 1.73
Increased by 39.29%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 693.0M | 861.0M | 1.0B | ||
| Avg | 653.9M | 756.9M | 849.6M | ||
| Low | 609.9M | 672.2M | 724.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.7% | 31.7% | 32.5% | ||
| Avg | -1.2% | 15.7% | 12.3% | ||
| Low | -7.9% | 2.8% | -4.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.21 | 2.82 | 3.83 | ||
| Avg | 1.73 | 2.41 | 3.44 | ||
| Low | 1.08 | 1.96 | 2.82 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 67.0% | 63.2% | 59.0% | ||
| Avg | 31.1% | 39.3% | 42.9% | ||
| Low | -18.3% | 13.3% | 17.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.